 |
12/18/2008
PTC THERAPEUTICS INITIATES TWO CLINICAL TRIALS OF PTC299 IN CANCER PATIENTS
|
11.1 KB |
| |
SOUTH PLAINFIELD, NJ - December 18, 2008 - PTC Therapeutics, Inc. (PTC) today announced the initiation of two clinical trials of the company's product candidate PTC299 in adult patients with solid tumor cancers and Kaposi Sarcoma, a HIV-related cancer. PTC299 is an orally delivered, investigational new drug that offers an innovative appro...
|
|
10/24/2008
PTC ANNOUNCES DATA SHOWING THAT PTC124 CAUSES STATISTICALLY SIGNIFICANT IMPROVEMENTS IN CHLORIDE CHANNEL FUNCTION IN CYSTIC FIBROSIS PATIENTS
|
15.2 KB |
| |
SOUTH PLAINFIELD, NJ AND ORLANDO, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) ...
|
|
09/30/2008
PTC THERAPEUTICS ANNOUNCES DATA SHOWING SIX-MINUTE WALK TEST CONSISTENTLY MEASURES AMBULATORY FUNCTION IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
|
12.7 KB |
| |
SOUTH PLAINFIELD, NJ – September 30, 2008 – PTC Therapeutics, Inc. (PTC) today announced promising findings in patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) at the 13th International World Muscle Society (WMS) Congress. Results from an observational study assessing the utility of the 6-minute walk test (6MWT) as a primary ou...
|
|
08/20/2008
PTC124 SHOWS PROMISING ACTIVITY IN CYSTIC FIBROSIS; PHASE 2 PROOF-OF-CONCEPT DATA PUBLISHED IN THE LANCET
|
13.3 KB |
| |
SOUTH PLAINFIELD, NJ - August 20, 2008 - New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with...
|
|
07/28/2008
PTC THERAPEUTICS HONORED FOR PATIENT ADVOCACY
|
7.7 KB |
| |
SOUTH PLAINFIELD, NJ - July 28, 2008- PTC Therapeutics, Inc. (PTC) today announced that the company was awarded the Art of Industry Partnership Award by the Genetic Alliance. Genetic Alliance presents the Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards annually.
"The Art of Industry Partnership Award honors a for-p...
|
|
07/17/2008
GENZYME CORPORATION AND PTC THERAPEUTICS ANNOUNCE COLLABORATION ON SMALL MOLECULE FOR GENETIC DISEASES
|
16.1 KB |
| |
CAMBRIDGE, MA and SOUTH PLAINFIELD, NJ - July 17, 2008 - Genzyme Corporation (Nasdaq: GENZ) and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations.
Under the terms o...
|
|
07/16/2008
PTC THERAPEUTICS ANNOUNCES $25 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF PTC124
|
12.5 KB |
| |
- Expanded Collaboration Supports Pivotal Phase 2b Clinical Trials of First Potential Therapy to Address an Underlying Cause of Cystic Fibrosis -
SOUTH PLAINFIELD, NJ and BETHESDA, MD - July 16, 2008- PTC Therapeutics, Inc. (PTC) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cysti...
|
|
06/12/2008
PTC THERAPEUTICS ANNOUNCES DATA FROM ADDITIONAL CLINICAL STUDIES OF PTC124 IN CYSTIC FIBROSIS CONFIRMING ACTIVITY
|
12.6 KB |
| |
South Plainfield, NJ and Prague, Czech Republic- June 12, 2008 - PTC Therapeutics, Inc. (PTC) today announced promising new data from two studies of PTC124 in cystic fibrosis (CF). Results from an Israeli Phase 2a extension study evaluating three months of oral PTC124 treatment in adult patients with nonsense-mutation-mediated CF d...
|
|
05/30/2008
PTC124 FEATURED AT THIRD ANNUAL CONGRESS OF MYOLOGY
|
10.9 KB |
| |
SOUTH PLAINFIELD, NJ- May 30, 2008- PTC Therapeutics, Inc. (PTC) today announced that PTC124, the company’s orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations, was featured in a symposium at Myology 2008, the Third Annual Congress of Myology, on Friday, May 30 in Marseil...
|
|
05/21/2008
PTC THERAPEUTICS ANNOUNCES DATA SUPPORTING COUGH FREQUENCY AS A NEW OUTCOME MEASURE IN EVALUATING TREATMENTS FOR CYSTIC FIBROSIS
|
11.6 KB |
| |
SOUTH PLAINFIELD, NJ- May 21, 2008- PTC Therapeutics, Inc. (PTC) today announced new data suggesting that the quantification of cough frequency may offer a clinically meaningful outcome measure in cystic fibrosis (CF). Cough is one of the most prominent and burdensome disease-related symptoms in CF. According to data presented toda...
|
|
04/23/2008
PTC THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2B REGISTRATION-DIRECTED CLINICAL TRIAL OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY
|
13.7 KB |
| |
SOUTH PLAINFIELD, N.J., April 23, 2008 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. (PTC), today announced the initiation of an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to dem...
|
|
02/04/2008
PTC THERAPEUTICS ANNOUNCES PUBLICATION OF PRECLINICAL DATA IN PNAS
|
11.9 KB |
| |
SOUTH PLAINFIELD, N.J., Feb 04, 2008 /PRNewswire via COMTEX News Network/ -- PTC Therapeutics, Inc. today announced the publication of new preclinical data in the February 12, 2008 edition of the Proceedings of the National Academy of Sciences (PNAS) which show that PTC124, a novel drug designed to bypass nonsense mutations, was active in a preclin...
|
| Showing 1-12 of 12 |
Page: 1 |
|
|